The distinctions between obesity-induced features occurring in the entire adipocyte population versus specific adipocyte subpopulations may explain the outstanding effectiveness of PPARγ agonists, such as thiazolidinediones, in improving adipose function and glucose homeostasis (Soccio et al., 2014), surpassing the effects of other anti-inflammatory or anti-stress reagents (Kraakman et al., 2015; Chen et al., 2016; da Cruz Nascimento et al., 2022). The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.